Therapeutic Antibodies for Biodefense

2017 ◽  
pp. 173-205 ◽  
Author(s):  
Arnaud Avril
Keyword(s):  
Therapeutic Antibodies

Role of convalescent plasma therapy in new Coronavirus disease (nCOVID-19): A review

2020 ◽  
Vol 11 (SPL1) ◽  
pp. 546-549
Author(s):  
Shweta Dadarao Parwe ◽  
Milind Abhimanyu Nisargandha ◽  
Rishikesh Thakre
Keyword(s):  
Clinical Trial ◽  
Immune Responses ◽  
Indian Population ◽  
Preventive Treatment ◽  
The Body ◽  
Therapeutic Antibodies ◽  
Plasma Therapy ◽  
Host Immune Responses ◽  
Transparent Liquid

Hitherto, there is no proper line of treatment for the new (nCOVID19). The development of unique antiviral drugs has taken precedence. Therapeutic antibodies () will be a significantly beneficial agent against nCOVID-19. Here the host immune responses to new discussed in this review provide strategy and further treatment and understanding of clinical interventions against nCOVID-19. Plasma therapy uses the antibodies found in the blood of people recovering (or convalesced) from an infection to treat infected patients. When an infection occurs, the body begins producing proteins specially made to kill the germ, called antibodies. Those antibodies coat specifically plasma in the blood of survivors, the yellow transparent liquid blood portion for months or even years. research assesses plasma use from Convalescent patients of infected with nCOVID-19 as a possible preventive treatment. But it is not yet recommended as a line of treatment, and it is used as a clinical trial in the new in Indian population.

Phage Display Derived Therapeutic Antibodies

2008 ◽  
Vol 9 (6) ◽  
pp. 439-446 ◽  
Author(s):  
Holger Thie ◽  
Torsten Meyer ◽  
Thomas Schirrmann ◽  
Michael Hust ◽  
Stefan Dubel
Keyword(s):  
Phage Display ◽  
Therapeutic Antibodies

Recent Patents Applications in Red Biotechnology: A Mini-Review

2019 ◽  
Vol 13 (3) ◽  
pp. 170-186 ◽  
Author(s):  
Raíssa C.D. Graciano ◽  
Júlia A.T. Ribeiro ◽  
Anderson K.S. Macêdo ◽  
José Paulo de S. Lavareda ◽  
Pedro R. de Oliveira ◽  
...  
Keyword(s):  
United States ◽  
Stem Cells ◽  
Cancer Research ◽  
Molecular Diagnostics ◽  
Literature Search ◽  
The United States ◽  
Therapeutic Antibodies ◽  
Diagnostic Kits

Background: The different fields of biotechnology can be classified by colors, as a "rainbow" methodology. In this sense, the red biotechnology, focused on the preservation of health, has been outstanding in helping to solve this challenge through the provision of technologies, including diagnostic kits, molecular diagnostics, vaccines, innovations in cancer research, therapeutic antibodies and stem cells. Objective: The main goal of this work is to highlight the different areas within the red Biotechnology. In this sense, we revised some patents regarding red biotechnology as examples to cover this subject. Methods: A literature search of patents was performed from the followings Patents Database: INPI, USPTO, Esp@cenet, WIPO and Google Patents. Results: Our analysis showed the following numbers from patents found: cancer research (8), diagnosis kit (9), vaccines (8), stem cells (9) and therapeutic antibodies (5), where the United States is the leader for most filled patents in Red Biotechnology. Conclusion: This mini-review has provided an update of some patents on Recent Patents in Red Biotechnology. As far as we know, this is the first mini-review report on Red Biotechnology based on patents.

scholarly journals Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas

2017 ◽  
Vol 8 ◽  
Author(s):  
Christian Schmitt ◽  
Anne Marie-Cardine ◽  
Armand Bensussan
Keyword(s):  
T Cell ◽  
Therapeutic Antibodies ◽  
T Cell Lymphomas

scholarly journals Therapeutic antibodies under development for SARS‐CoV‐2

View ◽  
2021 ◽  
pp. 20200178
Author(s):  
Zetong Ma ◽  
MengMei Zhu ◽  
Shuyi Zhang ◽  
Kewen Qian ◽  
Chuqi Wang ◽  
...  
Keyword(s):  
Therapeutic Antibodies

scholarly journals pH-responsive antibodies for therapeutic applications

2021 ◽  
Vol 28 (1) ◽  
Author(s):  
Tomasz Klaus ◽  
Sameer Deshmukh
Keyword(s):  
Drug Delivery ◽  
Treatment Outcome ◽  
Tumor Microenvironment ◽  
Dependent Manner ◽  
Therapeutic Antibodies ◽  
Ph Responsive ◽  
Biologic Drugs ◽  
Car T ◽  
Ph Dependent ◽  
The Brain

AbstractTherapeutic antibodies are instrumental in improving the treatment outcome for certain disease conditions. However, to enhance their efficacy and specificity, many efforts are continuously made. One of the approaches that are increasingly explored in this field are pH-responsive antibodies capable of binding target antigens in a pH-dependent manner. We reviewed suitability and examples of these antibodies that are functionally modulated by the tumor microenvironment. Provided in this review is an update about antigens targeted by pH-responsive, sweeping, and recycling antibodies. Applicability of the pH-responsive antibodies in the engineering of chimeric antigen receptor T-cells (CAR-T) and in improving drug delivery to the brain by the enhanced crossing of the blood–brain barrier is also discussed. The pH-responsive antibodies possess strong treatment potential. They emerge as next-generation programmable engineered biologic drugs that are active only within the targeted biological space. Thus, they are valuable in targeting acidified tumor microenvironment because of improved spatial persistence and reduced on-target off-tumor toxicities. We predict that the programmable pH-dependent antibodies become powerful tools in therapies of cancer.

scholarly journals CD4+ levels control the odds of induction of humoral immune responses to tracer doses of therapeutic antibodies

PLoS ONE ◽  
2017 ◽  
Vol 12 (11) ◽  
pp. e0187912 ◽  
Author(s):  
Sharat Srinivasula ◽  
Erin Gabriel ◽  
Insook Kim ◽  
Paula DeGrange ◽  
Alexis St Claire ◽  
...  
Keyword(s):  
Immune Responses ◽  
Therapeutic Antibodies ◽  
Humoral Immune ◽  
Humoral Immune Responses
Sign in / Sign up

Export Citation Format

Share Document